Adriana Tremoulet, MD, MAS
Adriana Tremoulet, MD, MAS, has been named co-director of the KL2 Program at UC San Diego Altman Clinical and Translational Research Institute (ACTRI). Dr. Tremoulet is a physician-scientist and is the associate director of the Kawasaki Disease Research Center at UC San Diego and the medical director of UC San Diego’s Pediatric Pharmacology Laboratory.
“We are delighted Dr. Tremoulet is joining ACTRI to co-lead the KL2 Program,” said Colin Depp, PhD, director of the ACTRI Education, Training and Career Development unit and co-director of the KL2 Program. “She is a role model and brings special expertise in mentorship, interdisciplinary research, and bridging the clinic with research.”
The KL2 program provides mentored career development funding support for junior faculty engaged in clinical and translational research. In this faculty position, Dr. Tremoulet will support mentorship of KL2 scholars and collaborate in developing new programs for junior faculty involved in clinical and translational research. The KL2 Program is a key component of ACTRI Education, which also oversees the TL1 pre-doctoral and post-doctoral training programs and Clinical Research Enhancement through Supplemental Training (CREST) program.
As a physician-researcher with a background in pharmacology, Dr. Tremoulet has conducted numerous clinical trials and cares for nearly 1,500 children with Kawasaki disease in San Diego County and an additional 100 children a year hospitalized at Rady Children's Hospital-San Diego. Kawasaki disease, an acute, self-limited vasculitis in childhood, is the leading cause of acquired heart disease in children in the United States and Japan. Dr. Tremoulet graduated from Harvard University with a major in biochemistry and attended medical school at the University of California, Los Angeles. During medical school, she spent a year as a fellow in the National Institutes of Health Clinical Research Training Program. She then completed her residency at Cedars-Sinai Medical Center and her pediatric infectious disease fellowship at UC San Diego. She then completed a Master in Advanced Studies of Clinical Research at UC San Diego in 2008. In 2013, she received support from ACTRI for a pilot project to study why some children with Kawasaki disease do not respond to standard treatment. She is the author or co-author of more than 70 publications in professional journals and was one of the featured speakers at the 2017 ACTRI Day of Translational Science.
For the next year, Dr. Tremoulet will work alongside Joel Dimsdale, MD, who has led the KL2 Program since 2010, in a transition period.
“We are extremely grateful to Dr. Dimsdale for his brilliance, dedication to mentoring, and leadership in building the KL2 program, and thankful he will retain a key role in KL2 program while Dr. Tremoulet assumes her new role,” Dr. Depp said.
About UC San Diego Altman Clinical and Translational Research Institute:
UC San Diego Altman Clinical and Translational Research Institute (ACTRI) is part of a national Clinical and Translational Science Award consortium, led by the National Institutes of Health National Center for Advancing Translational Science. Established in 2010, ACTRI provides infrastructure and support for basic, translational and clinical research throughout the San Diego region to bring discoveries from the laboratory to the bedside, and facilitates training and education of the next generation of researchers. ACTRI carries out its activities in collaboration with institutional and corporate partners and currently has more than 1,500 members.